Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin

Oncogene

Volumn 21, Issue 46, 2002, Pages 7131-7136

  Viniegra, Juan Guinea ^a   Losa, Javier Hernández ^a   Sánchez Arévalo, Victor Javier ^a   Cobo, Carlos Parada ^a   Soria, Victor Manuel Fernández ^a   Ramón y Cajal, Santiago ^a   Sánchez Prieto, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Akt; Cisplatin; Downregulation; E1a; Insulin; PI3k

Indexed keywords

CISPLATIN; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; VIRUS PROTEIN;

ADENOVIRUS; ARTICLE; CELL STRAIN COS7; CELL TRANSFORMATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; COS CELLS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; INSULIN; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

ADENOVIRIDAE;

EID: 0037057320     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1205934     Document Type: Article

References (26)

1. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P and Hemmings BA. (1996). EMBO J., 15, 6541-6551.
2. Brognard J, Clark AS, Ni Y and Dennis PA. (2001). Cancer Res., 61, 3986-3997.
3. Franza Jr BR, Maruyama K, Garrels JI and Ruley HE. (1986). Cell, 44, 409-418.
4. Frisch SM. (2001). Adv. Cancer Res., 80, 39-49.
5. Frisch SM and Mymryk JS. (2002). Nat. Rev. Mol. Cell. Biol., 3, 441-452.
6. Gallimore PH and Turnell AS. (2001). Oncogene, 20, 7824-7835.
7. Guo S, Cichy SB, He X, Yang Q, Ragland M, Ghosh AK, Johnson PF and Unterman TG. (2001). J. Biol. Chem., 276, 8516-823.
8. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T and Murata Y. (2000). Cancer Res., 60, 5988-5994.
9. Kim HS, Lee JK and Tsai SY. (1995). Mol. Endocrinol., 9, 178-186.
10. Lee WP, Liao Y, Robinson D, Kung HJ, Liu ET and Hung MC. (1999). Mol. Cell. Biol., 19, 8075-8082.
11. Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M and Hemmings BA. (2001). Science, 294, 374-380.
12. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC and Testa JR. (2000). Cancer Res., 60, 5390-5394.
13. Ng SS, Tsao MS, Nicklee T and Hedley DW. (2001). Clin. Cancer Res., 7, 3269-3275.
14. Razzini G, Berrie CP, Vignati S, Broggini M, Mascetta G, Brancaccio A and Falasca M. (2000). FASEB J., 14, 1179-1187.
15. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD and Downward J. (1994). Nature, 370, 527-532.
16. Saltiel AR and Kahn CR. (2001). Nature. 414, 799-806.
17. Sanchez-Prieto R, Quintanilla M, Cano A, Leonart ML, Martin P, Anaya A and Ramon y Cajal S. (1996). Oncogene, 13, 1083-1092.
18. See RH and Shi Y. (1998). Mol. Cell. Biol., 18, 4012-4022.
19. Shao R, Karunagaran D, Zhou BP, Li K, Lo SS, Deng J, Chiao P and Hung MC. (1997). J. Biol. Chem., 272, 32739-32742.
20. Shao R, Tsai EM, Wei K, von Lindern R, Chen YH, Makino K and Hung MC. (2001). Cancer Res., 61, 7413-7416.
21. Shayesth L, Lu Y, Kuo W, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powel B, Mills G and Gray J. (1999). Nature Genetics, 21, 99-102.
22. Simpson L and Parsons R. (2001). Exp. Cell Res., 264, 29-41.
23. Stein RW and Whelan J. (1989). Mol. Cell. Biol., 9, 4531-4534.
24. Teodoro JG, Shore GC and Branton PE. (1995). Oncogene, 11, 467-474.
25. Whalen SG, Marcellus RC, Whalen A, Ahn NG, Ricciardi RP and Branton PE. (1997). J. Virol., 71, 3545-3553.
26. Yu D, Suen TC, Yan DH, Chang LS and Hung MC. (1990). Proc. Natl. Acad. Sci. USA, 87, 4499-4503.